Lillys Mounjaro (tirzepatide.), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Although retatrutide is showing promising results in clinical trials, it has not yet been FDA approved, so conclusions cant be made around it being the best weight loss solution
Sometimes with a Reddit thread highlighted
The incidence is slightly higher than with semaglutide (13%) due to tirzepatides dual GIP and GLP-1 receptor agonism, which creates more pronounced metabolic and autonomic nervous system shifts
Retatrutide represents the next generation of weight loss medications, developed by Eli Lilly as a once-weekly injectable peptide that targets three distinct metabolic pathways simultaneously
doi: 10.1016/j.chom.2014.09.001 77 RothhammerVBoruckiDMGarcia SanchezMIMazzolaMAHemondCCRegevKet al